This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated coverage: VYLR Outperform/$85, LBRX Buy/$68, ELVN Overweight/$70, SAIL Sector Weight, and AVLN Outperform/$60.
Stocks · News reference
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's strong CML trial data & $8.8B market potential.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Morgan Stanley Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $70
Morgan Stanley analyst Sean Laaman initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $70.
JP Morgan Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $75
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight
The chronic myeloid leukemia (CML) clinical trial pipeline shows robust activity with 25+ pharmaceutical companies developing 25+ pipeline drugs. Key players including Merck, Enliven Therapeutics, ImmunoForge, and others are advancing promising therapies like TERN-701, ELVN-001, and KF1601 across various clinical stages. The market is evolving from established tyrosine kinase inhibitors toward newer selective agents targeting resistance, intolerance, and treatment-free remission.
Europe Cancer Metabolism Based Therapeutics Market Forecast to 2035 by Modality, Route, Indication, and Therapy Sales | 25.3% CAGR Drives an $8.54 Billion Opportunity
Europe's cancer metabolism-based therapeutics market is projected to grow from $1.12 billion in 2026 to $8.54 billion by 2035, representing a 25.3% CAGR. Growth is driven by Europe's high cancer burden, advances in molecular profiling, precision oncology adoption, and regulatory validation. Small molecules and oral administration routes dominate, with breast cancer and non-small cell lung cancer as leading indications. Key players include AstraZeneca, Bayer, Novartis, Roche, and Servier.
Autoimmune CAR T Safety Events Reshape Rheumatologist Sentiment, but Autologous CAR T Retains Lead, According to Spherix Global Insights
Following trial pauses by Novartis and Bristol Myers Squibb due to safety concerns, rheumatologist confidence in autologous CAR T dropped significantly from 7.5 to 5.2 on a 10-point scale. Despite this, autologous CAR T retained its lead among immune reset modalities at 49% preference. Systemic sclerosis emerged as the clearest near-term opportunity, while delivery infrastructure and safety evidence are now critical differentiators for market adoption.